US20070213290A1
(en)
*
|
1996-10-17 |
2007-09-13 |
Kingsman Alan J |
Neurite regeneration
|
US6818209B1
(en)
*
|
1998-05-22 |
2004-11-16 |
Oxford Biomedica (Uk) Limited |
Retroviral delivery system
|
US20040076613A1
(en)
*
|
2000-11-03 |
2004-04-22 |
Nicholas Mazarakis |
Vector system
|
US7635687B2
(en)
*
|
1997-06-04 |
2009-12-22 |
Oxford Biomedica (Uk) Limited |
Vector system
|
EP1017797B1
(de)
*
|
1997-09-24 |
2005-06-22 |
The Regents Of The University Of California |
Nicht-primaten lentivirale vektoren und verpackungssysteme
|
GB2345062B
(en)
*
|
1997-12-22 |
2001-07-25 |
Oxford Biomedica Ltd |
Retroviral vectors
|
DK1895010T3
(da)
*
|
1997-12-22 |
2011-11-21 |
Oxford Biomedica Ltd |
Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
|
GB9803351D0
(en)
*
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
US6790657B1
(en)
|
1999-01-07 |
2004-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Lentivirus vector system
|
AU2495300A
(en)
*
|
1999-01-07 |
2000-07-24 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Lentivirus vector system
|
WO2000055335A1
(en)
*
|
1999-03-16 |
2000-09-21 |
Dana-Farber Cancer Institute, Inc. |
Pseudotyped lentiviral vectors and uses thereof
|
CN1173036C
(zh)
|
1999-04-21 |
2004-10-27 |
卫生部艾滋病预防与控制中心 |
马传染性贫血病毒驴白细胞弱毒疫苗株的全长基因序列
|
EP1964573B1
(de)
|
1999-10-22 |
2014-11-26 |
Aventis Pasteur Limited |
Verfahren zur Induzierung und/oder Verbesserung einer Immunreaktion auf Tumorantigene
|
CN1321182C
(zh)
*
|
1999-12-30 |
2007-06-13 |
卫生部艾滋病预防与控制中心 |
马传染性贫血病毒代表毒株的全基因克隆及其应用
|
GB0009760D0
(en)
*
|
2000-04-19 |
2000-06-07 |
Oxford Biomedica Ltd |
Method
|
US7851212B2
(en)
*
|
2000-05-10 |
2010-12-14 |
Sanofi Pasteur Limited |
Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
|
JP2004522697A
(ja)
*
|
2000-09-09 |
2004-07-29 |
アクゾ・ノベル・エヌ・ベー |
Eiavキメラワクチンおよび診断
|
GB0024550D0
(de)
*
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
US7575924B2
(en)
|
2000-11-13 |
2009-08-18 |
Research Development Foundation |
Methods and compositions relating to improved lentiviral vectors and their applications
|
WO2002079482A2
(en)
*
|
2000-11-16 |
2002-10-10 |
Rigel Pharmaceuticals, Inc. |
In vitro transcribed retroviral genomes, methods for their production and methods of use
|
US6712612B1
(en)
|
2000-12-12 |
2004-03-30 |
Genecure Llc |
Safe and stable retroviral helper cell line and related compositions and methods
|
IL157335A0
(en)
|
2001-03-13 |
2004-02-19 |
Novartis Ag |
Lentiviral packaging constructs
|
US7211247B2
(en)
|
2001-04-09 |
2007-05-01 |
University Of Southern California |
Lentivirus vectors for gene transfer to alveolar epithelial cells
|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
AU2002327412A1
(en)
|
2001-08-02 |
2003-02-17 |
Institut Clayton De La Recherche |
Methods and compositions relating to improved lentiviral vector production systems
|
NZ532060A
(en)
|
2001-10-02 |
2005-11-25 |
Inst Clayton De La Rech |
Methods and compositions relating to restricted expression lentiviral vectors and their applications
|
JP4497923B2
(ja)
|
2001-12-05 |
2010-07-07 |
ザ ジェイ. デビッド グラッドストーン インスティテューツ |
ロボット顕微鏡検査システム
|
WO2005035773A2
(en)
*
|
2003-10-08 |
2005-04-21 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
CN1658899B
(zh)
|
2002-04-09 |
2013-01-02 |
安万特巴斯德有限公司 |
经修饰的cea核酸及表达载体
|
ATE424464T1
(de)
*
|
2002-04-26 |
2009-03-15 |
Inst Nat Sante Rech Med |
Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren
|
WO2004044157A2
(en)
*
|
2002-11-12 |
2004-05-27 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Human Services, The National Institutes Of Health |
Gp64-pseudotyped vectors and uses thereof
|
DK1563069T3
(da)
*
|
2002-11-22 |
2012-07-23 |
Inst Clayton De La Rech |
Sammensætninger og systemer til genregulering
|
JP2006516548A
(ja)
|
2002-12-30 |
2006-07-06 |
アンジオテック インターナショナル アクツィエン ゲゼルシャフト |
迅速ゲル化ポリマー組成物からの薬物送達法
|
US8026819B2
(en)
*
|
2005-10-02 |
2011-09-27 |
Visible Assets, Inc. |
Radio tag and system
|
AU2004269233A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Kaneka Corporation |
Method of constructing transgenic bird using lentivirus vector and transgenic bird obtained thereby
|
EP1773403B1
(de)
*
|
2004-07-09 |
2018-04-25 |
The University of North Carolina At Chapel Hill |
Auf alphavirus basierende adjuvanzien
|
US8486420B2
(en)
*
|
2005-02-15 |
2013-07-16 |
The University Of North Carolina At Chapel Hill |
Live virus vaccines
|
WO2007089780A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Licentia, Ltd. |
Bmx/etk tyrosine kinase gene therapy materials and methods
|
US8105575B2
(en)
*
|
2006-10-10 |
2012-01-31 |
Viromed Co., Ltd. |
Expression vectors with improved safety
|
EP2089513A1
(de)
|
2006-12-07 |
2009-08-19 |
Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum |
Verwendung eines varicellovirus-tap-hemmers zur induktion von tumor- oder virenspezifischer immunität gegen teipp
|
CN101705246B
(zh)
*
|
2007-04-29 |
2012-06-27 |
中国农业科学院哈尔滨兽医研究所 |
慢病毒基因转移载体、其制备方法和应用
|
AU2008314485B9
(en)
|
2007-10-15 |
2015-02-26 |
Jingang Medicine (Australia) Pty Ltd |
Expression system for modulating an immune response
|
CA2705862C
(en)
|
2007-11-16 |
2018-03-27 |
San Diego State University Research Foundation |
Compositions and method for manipulating pim-1 activity in circulatory system cells
|
WO2010087702A1
(en)
|
2009-01-30 |
2010-08-05 |
Stichting Katholieke Universiteit |
TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
|
US9752124B2
(en)
|
2009-02-03 |
2017-09-05 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising the stem cells
|
EP2412800A1
(de)
|
2010-07-29 |
2012-02-01 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Leberorganoid, Verwendungen davon und Kultivierungsverfahren zum Erhalten davon
|
US8642339B2
(en)
|
2009-02-03 |
2014-02-04 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
Culture medium for epithelial stem cells and organoids comprising the stem cells
|
CN101532031B
(zh)
*
|
2009-03-03 |
2011-04-20 |
上海吉盛制药技术有限公司 |
非整合慢病毒载体系统及其制备与应用
|
EP2478101A1
(de)
|
2009-09-16 |
2012-07-25 |
Stichting Het Nederlands Kanker Instituut |
Fra-1-zielgene als wirkstofftargets zur behandlung von krebs
|
EP2305717A1
(de)
|
2009-09-21 |
2011-04-06 |
Koninklijke Nederlandse Akademie van Wetenschappen |
Hemmung von TNIK zur Behandlung von Darmkrebs
|
EP2319918B1
(de)
|
2009-11-10 |
2013-01-16 |
Centre National De La Recherche Scientifique |
Vektor auf Lentivirus beruhend und dessen Verwendung bei der zielgerichteten Evolution von genomischen Regionen, Genen und Polynukleotiden
|
WO2011066578A1
(en)
*
|
2009-11-30 |
2011-06-03 |
American Gene Technologies International Inc. |
Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
|
US9795658B2
(en)
|
2010-04-20 |
2017-10-24 |
Admedus Vaccines Pty Ltd |
Expression system for modulating an immune response
|
CA3128549A1
(en)
|
2010-07-12 |
2012-01-19 |
Universitat Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
WO2012047093A1
(en)
|
2010-10-05 |
2012-04-12 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Treatment of the sjögren's syndrome
|
EP2465928A1
(de)
|
2010-12-16 |
2012-06-20 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam |
Behandlung von Th17-vermittelten Krankheiten
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
US9347065B2
(en)
|
2012-03-29 |
2016-05-24 |
International Aids Vaccine Initiative |
Methods to improve vector expression and genetic stability
|
EP2866826A1
(de)
|
2012-06-27 |
2015-05-06 |
Arthrogen BV |
Kombination zur behandlung einer entzündlichen erkrankung
|
SI2852668T1
(sl)
|
2012-07-12 |
2016-09-30 |
Proqr Therapeutics Ii B.V. |
Oligonukleotidi za izvedbo spremembe v sekvenci tarčne molekule rna, prisotne v živeči celici
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
US9730996B2
(en)
|
2012-10-24 |
2017-08-15 |
Texas Biomedical Research Institute |
Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
|
CA2906643A1
(en)
|
2013-03-15 |
2014-09-25 |
The Jackson Laboratory |
Isolation of non-embryonic stem cells and uses thereof
|
CA2924013A1
(en)
|
2013-11-05 |
2015-05-14 |
Clontech Laboratories, Inc. |
Dry transfection compositions and methods for making and using the same
|
US10654908B2
(en)
|
2014-04-15 |
2020-05-19 |
University Of Virginia Patent Foundation |
Isolated T cell receptors and methods of use therefor
|
EP3031923A1
(de)
*
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
|
EP3978614A3
(de)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
|
JP7089469B2
(ja)
|
2015-10-23 |
2022-06-22 |
ザ ジャクソン ラボラトリー |
眼神経変性障害(例えば緑内障)の処置及び予防における使用のためのニコチンアミド
|
WO2017091786A1
(en)
|
2015-11-23 |
2017-06-01 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
US10596248B2
(en)
|
2015-12-09 |
2020-03-24 |
Jingang Medicine (Australia) Pty Ltd |
Immunomodulating composition for treatment
|
EP3469362A1
(de)
|
2016-06-10 |
2019-04-17 |
Gadeta B.V. |
Menschliche leukozyten-antigen-beschränkte gamma-delta-t-zell-rezeptoren und verfahren zur verwendung davon
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
JP2020506695A
(ja)
|
2017-01-30 |
2020-03-05 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
糖原病を処置するための組換えウイルスベクター
|
US20200102361A1
(en)
|
2017-05-24 |
2020-04-02 |
Universitat Autònoma De Barcelona |
Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence
|
EP3648776A4
(de)
|
2017-07-06 |
2021-04-07 |
The Medical College of Wisconsin, Inc. |
Neue in-vitro- und in-vivo-anreichungsstrategie gegen lymphozyten aus vektortransduzierten hsc zur behandlung von erkrankungen
|
WO2019133810A1
(en)
|
2017-12-28 |
2019-07-04 |
Tract Pharmaceuticals, Inc. |
Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
|
WO2019219979A1
(en)
|
2018-05-18 |
2019-11-21 |
Umc Utrecht Holding B.V. |
Compositions and methods for cell targeting therapies
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
AU2019387218A1
(en)
|
2018-11-26 |
2021-06-03 |
Massachusetts Institute Of Technology |
Compositions and methods for immune tolerance
|
AU2019389253A1
(en)
|
2018-11-26 |
2021-06-10 |
Universitat Autonoma De Barcelona |
Fibroblast growth factor 21 (FGF21) gene therapy
|
JP2022534733A
(ja)
|
2019-05-31 |
2022-08-03 |
ウニベルシダッド アウトノマ デ バルセロナ |
インスリン遺伝子治療
|
EP4143326A1
(de)
|
2020-04-27 |
2023-03-08 |
University of Iowa Research Foundation |
Zusammensetzungen und verfahren zur behandlung von zystischer fibrose
|
CN115916985A
(zh)
|
2020-05-26 |
2023-04-04 |
巴塞罗那自治大学 |
用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法
|
CA3184784A1
(en)
*
|
2020-05-27 |
2021-12-02 |
The Medical College Of Wisconsin, Inc. |
Improved lentiviral vector transfer plasmid and methods of use
|
JP2023552531A
(ja)
|
2020-12-10 |
2023-12-18 |
サレプタ セラピューティクス, インコーポレイテッド |
接着細胞のための懸濁モードシードトレイン開発
|
WO2022162067A1
(en)
|
2021-01-30 |
2022-08-04 |
Universitat Autònoma De Barcelona |
Gene therapy for monogenic diabetes
|
WO2022221462A1
(en)
|
2021-04-13 |
2022-10-20 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic vlcad or mcad and methods of using the same
|
EP4089171A1
(de)
|
2021-05-12 |
2022-11-16 |
Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Rekombinante tert-codierende virale genome und vektoren
|
WO2022258606A1
(en)
|
2021-06-07 |
2022-12-15 |
Gadeta B.V. |
Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
EP4370677A1
(de)
|
2021-07-16 |
2024-05-22 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
Oligonukleotid zur hemmung der anking-aktivität
|
WO2023212683A1
(en)
|
2022-04-29 |
2023-11-02 |
Kriya Therapeutics, Inc. |
Insulin and glucokinase gene therapy compositions and its use for treating diabetes
|
WO2023227594A1
(en)
|
2022-05-24 |
2023-11-30 |
Gadeta Bv |
Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
|
WO2023237541A1
(en)
|
2022-06-07 |
2023-12-14 |
Gadeta B.V. |
Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
|
WO2024013402A1
(en)
|
2022-07-15 |
2024-01-18 |
Gadeta B.V. |
Novel soluble gamma t-cell (or soluble delta t-cell) receptor chains (or soluble gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
|
WO2024052413A1
(en)
|
2022-09-07 |
2024-03-14 |
Universitat Autònoma De Barcelona |
Beta-hexosaminidase vectors
|
WO2024100136A1
(en)
|
2022-11-08 |
2024-05-16 |
Gadeta B.V. |
Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
|